Skip to content
2000
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882

Abstract

Background

Antibody titres against several infections are hypothesized to be protective against COVID-19 due to cross-immunity. The study intends to assess the relationship between historical data of measles, rubella, pertussis antibody titres and the occurrence of self-reported COVID-19.

Methods

The study was conducted as an online cross-sectional survey which was compared with historical data of antibody titers. The university female students who had participated in our previous study evaluating seroprevalence of measles, rubella and pertussis antibody titres were contacted online for the survey. The online questionnaire was sent to collect details on COVID-19 occurrence among all the participants. The measles, rubella and pertussis titers of all participants were correlated with the present questionnaire data. All volunteers participated in the survey after online informed consent.

Results

Among the 52 responders to the questionnaire, 18 participants had been reported to be suffering from COVID-related symptoms and 12 were reported to have confirmed RT-PCR positive for COVID-19. The unpaired “t” test comparing antibody titres of measles, rubella and pertussis between COVID-19 RT PCR positive and RT PCR negative subjects did not show statistical significance.

Conclusion

There was no statistical difference between antibody titers of measles, rubella and pertussis among self-reported COVID-19 RT PCR positive and RT PCR negative university female students.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882260080231017114807
2024-01-01
2025-04-23
The full text of this item is not currently available.

References

  1. KarlinskyA. KobakD. Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset.eLife202110e6933610.7554/eLife.6933634190045
    [Google Scholar]
  2. AlkholyU.M. SalamaM.E. MahmoudH. TaherA. ElsayesK.M. Could Bordetella pertussis vaccine protect against coronavirus COVID-19?J. Glob. Antimicrob. Resist.20202280380510.1016/j.jgar.2020.07.00532682930
    [Google Scholar]
  3. AnbarasuA. RamaiahS. LivingstoneP. Vaccine repurposing approach for preventing COVID 19: Can MMR vaccines reduce morbidity and mortality?Hum. Vaccin. Immunother.20201692217221810.1080/21645515.2020.177314132501133
    [Google Scholar]
  4. CoviánC. Retamal-DíazA. BuenoS.M. KalergisA.M. Could BCG Vaccination induce protective trained immunity for SARS-CoV-2?Front. Immunol.20201197010.3389/fimmu.2020.0097032574258
    [Google Scholar]
  5. BayramZ. MusharrafiehU. BizriA.R. Revisiting the potential role of BCG and MMR vaccines in COVID-19.Sci. Prog.2022105236850422110517210.1177/0036850422110517235848578
    [Google Scholar]
  6. SharmaD. Repurposing of the childhood vaccines: Could we train the immune system against the SARS-CoV-2.Expert Rev. Vaccines20212091051105710.1080/14760584.2021.196016134313516
    [Google Scholar]
  7. FonteL. GinoriM. GarcíaG. HernándezY. de ArmasY. CalderónE.J. Nonspecific effects of infant vaccines make children more resistant to SARS-CoV-2 infection.Children2022912185810.3390/children912185836553302
    [Google Scholar]
  8. GurselM. GurselI. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?Allergy20207571815181910.1111/all.1434532339299
    [Google Scholar]
  9. KlingerD. BlassI. RappoportN. LinialM. Significantly improved COVID-19 outcomes in countries with higher BCG vaccination coverage: A multivariable analysis.Vaccines20208337810.3390/vaccines803037832664505
    [Google Scholar]
  10. SidiqK.R. SabirD.K. AliS.M. KodziusR. Does early childhood vaccination protect against COVID-19?Front. Mol. Biosci.2020712010.3389/fmolb.2020.0012032582766
    [Google Scholar]
  11. IettoG. SARS – CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis).Med. Hypotheses202014110977910.1016/j.mehy.2020.10977932387756
    [Google Scholar]
  12. FidelP.L.Jr NoverrM.C. Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection?MBio2020113e00907-2010.1128/mBio.00907‑2032561657
    [Google Scholar]
  13. IsmailM.B. OmariS.A. RafeiR. DabboussiF. HamzeM. COVID-19 in children: Could pertussis vaccine play the protective role?Med. Hypotheses202014511030510.1016/j.mehy.2020.11030533032174
    [Google Scholar]
  14. JhancyM BernhardtGV SrinivasamurthyS AkramWM HarisAS Seroprevalence of pertussis antibodies and infection risk among female medical students.New Emir. Med. J.2022321510.2174/03666220816103424
    [Google Scholar]
  15. AlharthyA. AletrebyW. FaqihiF. BalhamarA. AlaklobiF. AlaneziK. JaganathanP. TamimH. AlqahtaniS.A. KarakitsosD. MemishZ.A. Clinical characteristics and predictors of 28-day mortality in 352 critically ill patients with COVID-19: A retrospective study.J. Epidemiol. Glob. Health20201119810410.2991/jegh.k.200928.00133095982
    [Google Scholar]
  16. IzadiN. ShahbaziF. MokhayeriY. SeifiA. TaherpourN. MehriA. FallahS. Sotoodeh GhorbaniS. Farhadi-BabadiK. TaherianM.R. RahimiE. EtemedK. Hashemi NazariS.S. Intensive care unit admission and associated factors in patients hospitalised for COVID-19: A national retrospective cohort study in Iran.BMJ Open2023138e07054710.1136/bmjopen‑2022‑07054737607784
    [Google Scholar]
  17. Taheri SoodejaniM. BastiM. TabatabaeiS.M. RajabkhahK. Measles, mumps, and rubella (MMR) vaccine and COVID-19: A systematic review.Int. J. Mol. Epidemiol. Genet.2021123353934336136
    [Google Scholar]
  18. GoldJ.E. BaumgartlW.H. OkyayR.A. LichtW.E. FidelP.L.Jr NoverrM.C. TilleyL.P. HurleyD.J. RadaB. AshfordJ.W. Analysis of measles-mumps-rubella (MMR) titers of recovered COVID-19 patients.MBio2020116e02628-2010.1128/mBio.02628‑2033219096
    [Google Scholar]
  19. NoverrM. YanoJ. HagenseeM. LinH. MeyaskiM. MeyaskiE. CameronJ. ShellitoJ. TrauthA. FidelP.Jr Effect of MMR vaccination to mitigate severe sequelae associated with COVID-19: Challenges and lessons learned.Med. Res. Arch.2023112359810.18103/mra.v11i2.359837153751
    [Google Scholar]
  20. KollaE. WeillA. DesplasD. SemenzatoL. ZureikM. GrimaldiL. Does measles, mumps, and rubella (MMR) vaccination protect against COVID-19 outcomes: A nationwide cohort study.Vaccines20221011193810.3390/vaccines1011193836423033
    [Google Scholar]
  21. SalamonyA. ShamikhY. AmerK. ElnagdyT. ElnakibM. YehiaA.A. HassanW. AbdelsalamM. Are measles-mumps-rubella (MMR) antibodies friends or foes for COVID-19 disease?Arch. Immunol. Ther. Exp.20237111510.1007/s00005‑023‑00680‑137341786
    [Google Scholar]
/content/journals/nemj/10.2174/0102506882260080231017114807
Loading
/content/journals/nemj/10.2174/0102506882260080231017114807
Loading

Data & Media loading...


  • Article Type:
    Research Article
Keyword(s): Antibody titers; COVID-19 immunity; Diseases; Measles; Seroprotection; University students
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test